Zacks: Analysts Expect Radius Health, Inc. (NASDAQ:RDUS) to Announce -$0.23 Earnings Per Share

Wall Street brokerages expect Radius Health, Inc. (NASDAQ:RDUS) to announce ($0.23) earnings per share for the current quarter, Zacks reports. Five analysts have made estimates for Radius Health’s earnings, with estimates ranging from ($0.26) to ($0.18). Radius Health posted earnings of ($0.14) per share during the same quarter last year, which would suggest a negative year over year growth rate of 64.3%. The firm is expected to report its next earnings report on Thursday, November 4th.

According to Zacks, analysts expect that Radius Health will report full-year earnings of ($0.92) per share for the current year, with EPS estimates ranging from ($1.26) to ($0.65). For the next fiscal year, analysts forecast that the company will report earnings of $0.84 per share, with EPS estimates ranging from $0.56 to $1.06. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Radius Health.

Radius Health (NASDAQ:RDUS) last issued its quarterly earnings data on Thursday, August 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.04. The business had revenue of $51.80 million for the quarter, compared to analysts’ expectations of $58.92 million.

Several research firms recently issued reports on RDUS. HC Wainwright cut their target price on Radius Health from $25.00 to $19.00 and set a “neutral” rating on the stock in a research report on Friday, August 6th. SVB Leerink upped their target price on Radius Health from $24.00 to $26.00 and gave the company a “market perform” rating in a research report on Friday, August 6th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $25.29.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada grew its position in Radius Health by 11.0% during the 1st quarter. Royal Bank of Canada now owns 5,434 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 538 shares during the period. Alps Advisors Inc. grew its position in shares of Radius Health by 1.0% during the 1st quarter. Alps Advisors Inc. now owns 84,838 shares of the biopharmaceutical company’s stock valued at $1,770,000 after acquiring an additional 840 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Radius Health by 3.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,027 shares of the biopharmaceutical company’s stock valued at $475,000 after acquiring an additional 885 shares during the period. Sei Investments Co. grew its position in shares of Radius Health by 4.3% during the 2nd quarter. Sei Investments Co. now owns 24,508 shares of the biopharmaceutical company’s stock valued at $447,000 after acquiring an additional 1,000 shares during the period. Finally, Virtus ETF Advisers LLC grew its position in shares of Radius Health by 2.8% during the 1st quarter. Virtus ETF Advisers LLC now owns 42,536 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 1,161 shares during the period.

Shares of NASDAQ RDUS traded up $0.06 during mid-day trading on Thursday, hitting $12.18. The stock had a trading volume of 317,317 shares, compared to its average volume of 382,251. The company has a 50 day moving average of $14.52 and a two-hundred day moving average of $18.25. Radius Health has a twelve month low of $10.15 and a twelve month high of $26.16. The firm has a market cap of $575.70 million, a PE ratio of -9.40 and a beta of 0.91.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women.

Featured Article: Debt-To-Equity Ratio

Get a free copy of the Zacks research report on Radius Health (RDUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.